---
title: >-
  Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face,
  and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort (RAD 2021)
description: >-
  Explore this publication on real-world evidence: Epidemiology and Burden of
  Atopic Dermatitis Involving the Head, Neck, Face, and Hand: A Cross Sectional…
date: '2021-05-10'
author: Breda Munoz, Julie M. Crawford
category: Publications
tags:
  - Atopic Dermatitis (AD)
  - Pharma Partner
  - 'Yes'
  - R&D
  - AbbVie Inc.
  - El Paso Dermatology
  - RAD Conference
  - Care
  - George Washington University
  - Health System Partner
  - Poster Presentation
  - Dermatology
  - UCSF
  - Mount Sinai
canonical_url: https://www.pedestalhealth.com/resources/publications/di-atopic-dermatitis/epidemiology-and-burden-of-atopic-dermatitis-involving-the/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: epidemiology-and-burden-of-atopic-dermatitis-involving-the
id: 6LnZE2omq8vUxYBUnVoCo9
contentType: article
---

# Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort (RAD 2021)

**AbbVie Inc.** · **El Paso Dermatology** · **George Washington University** · **UCSF** · **Mount Sinai**

*Breda Munoz, Julie M. Crawford*

## Challenge

This is the RAD 2021 poster—the earliest presentation—of the head, neck, face, and hand AD burden findings that were subsequently published in manuscript form (Row 10) and presented at Fall Clinical 2022 (Row 35). First dissemination of the finding that difficult-to-treat site involvement affects 85% of moderate-to-severe AD patients.

## Solution

TARGET-DERM AD cohort cross-sectional analysis of difficult-to-treat AD site prevalence and HRQoL impact (POEM, DLQI/CDLQI) at RAD 2021.

## Impact

Initial conference dissemination of the difficult-to-treat site burden data at RAD 2021 established the evidence foundation for subsequent manuscript publication and multi-venue dissemination, directly informing AbbVie's body-site-specific label development strategy for AD therapies.

## Use Cases / Links

First dissemination of difficult-to-treat AD site burden evidence establishing foundation for multi-venue publication strategy, Anatomical disease burden data initiating the evidence base for body-site-specific AD label development, RAD 2021 evidence launch supporting AbbVie and other sponsors' difficult-to-treat site AD programs

